


Development



The leading primary research journal in the field of developmental biology launched in 1953, Development publishes cutting-edge articles and reviews across the spectrum of plant and animal development.

Topic coverage ranges from stem cells and nuclear reprogramming to evolutionary developmental and systems biology, from neurobiology to regional specification, morphogenesis and organogenesis, and from epigenetics to the aetiology of disease.

In addition to primary research articles, Development publishes a range of commissioned review-based articles. These synthesise the latest advances in the field, put forward new hypotheses to provoke debate and inspire new research directions, and inform newcomers to the field.

Development was designated as one of the 100 most influential journals of the past 100 years by the SLA BioMedical & Life Sciences Division in 2019.

Readership

Development is read by scientists at all levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, paediatricians, neurologists, embryologists and stem cell scientists.

Abstracting and indexing services

Development is abstracted and/or indexed (amongst others) by: BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, ISI Web of Science, Medline and SCOPUS.

Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals (including Development) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are also included in our Read & Publish Open Access agreements.

- 2021 Impact Factor: 6.862
- Five-year Impact Factor: 7.799
- Two-year citation median: 4.0
- Eigenfactor Score: 0.05234
- Article Influence Score: 2.738
- Immediacy index: 1.008
- h-index: 336
- Scopus CiteScore: 9.7
- SJR indicator: 2.886
- SNIP: 1.622

Development

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

• James Briscoe (Francis Crick Institute, UK)

Deputy Editor

• Steve Wilson (University College London, UK)

Editors

- Swathi Arur (MD Anderson Cancer Center, USA)
- Benoit Bruneau (Gladstone Institutes, USA)
- · Cassandra Extavour (Harvard University, USA)
- François Guillemot (Francis Crick Institute, UK)
- · Yka Helariutta (University of Cambridge, UK)
- Haruhiko Koseki (RIKEN Centre for Allergy and Immunology, Japan)
- · Thomas Lecuit (Marseille University, France)
- Liz Robertson (University of Oxford, UK)
- · Debra Silver (Duke University, USA)
- · Patrick Tam (University of Sydney, Australia)
- Maria Elena Torres-Padilla (Helmholtz Centre, Munich, Germany)
- James Wells (Cincinatti Children's Hospital Medical Center, USA)

Associate Editors

- Paul François (McGill University, Canada)
- Matthias Lutolf (École Polytechnique Fédérale de Lausanne, Switzerland)
- Irene Miguel-Aliaga (Imperial College London and MRC-LMS, UK)
- · Hanna Mikkola (University of California, Los Angeles, USA)
- Samantha Morris (Washington University in St Louis, USA)
- · Ken Poss (Duke University, USA)


What are the benefits of Read & Publish agreements?

- Unlimited "read" access to our three subscription journals Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- · Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- · Compliant with funder mandates including Plan S
- What a wonderful surprise it was to find out about the Read & Publish Open Access agreement between The Company of Biologists and my university which facilitates immediate access to our research to all readers without charge!


This is fabulous: for science, for our trainees whose careers benefit from having their research seen quickly and widely, and for our hard-earned publicly funded research grants that can advance science further as a result.

I love this initiative.

Professor Jacquetta Trasler, McGill University, Canada




Figures based on the latest available data from Impact Vizor and Altmetric Explorer





Journal of Cell Science



Launched in 1853, Journal of Cell Science publishes cutting-edge articles and reviews encompassing all aspects of cell biology – from the inner workings of individual cells to how they react and respond to each other and their environment.

Topics covered range from cell signalling, cell migration, cell adhesion, cell division and cell polarity, through to cancer cell biology, immunology, biochemistry and mechanobiology.

In addition to primary research articles,
Journal of Cell Science publishes a range of
commissioned review-based articles. These
articles synthesise the latest advances in the field,
put forward new hypotheses to provoke debate
and inspire new research directions, and inform
newcomers to the field.

Readership

Journal of Cell Science is read by a broad spectrum of scientists at all levels, including cell biologists, developmental biologists, molecular biologists, plant biologists and neuroscientists.

Abstracting and indexing services

Journal of Cell Science is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline and Scopus.

Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals (including Journal of Cell Science) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are also included in our Read & Publish Open Access agreements.

- 2021 Impact Factor: 5.235
- Five-year Impact Factor: 6.129
- Two-year citation median: 3.0
- Eigenfactor score: 0.03341
- Article Influence Score: 1.876
- Immediacy Index: 1.355
- h-index: 289
- Scopus CiteScore: 7.8
- SJR indicator: 1.936
- SNIP: 1.237

Journal of **Cell Science**

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

• Michael Way (The Francis Crick Institute, UK)

Deputy Editor-in-Chief

 Kathleen J. Green (Northwestern University Medical School, USA)


Editors

- Daniel Billadeau (Mayo Clinic, USA)
- Maria Carmo-Fonseca (Institute of Molecular Medicine Lisboa, Portugal)
- Andrew Ewald (Johns Hopkins School of Medicine, USA)
- David M. Glover (California Institute of Technology, USA)
- John K. Heath (University of Birmingham, UK)
- Caroline Hill (The Francis Crick Institute, UK)
- Jennifer Lippincott-Schwartz (Janelia Research Campus, USA)
- Guangshuo Ou (Tsinghua University, China)
- Giampietro Schiavo (University College London, UK)
- Mahak Sharma (Indian Institute of Science Education and Research Mohali, India)
- Arnoud Sonnenberg (The Netherlands Cancer Institute, The Netherlands)
- David Stephens (University of Bristol, UK)
- Tamotsu Yoshimori (Osaka University, Japan)


What are the benefits of Read & Publish agreements?

- Unlimited "read" access to our three subscription journals Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S
- I was thrilled to see that Journal of Cell Science was part of a Read & Publish agreement with the University of Liverpool. It makes the publishing process fast and free of charge for authors. For scientists with limited funding such as early-career researchers, this allows the best research to be published in the best journals without having to think about the financial implications. I wish all publishers would follow the steps of The Company of Biologists.

Dr Nordine Helassa, University of Liverpool, UK









Journal of **Experimental Biology**



Launched in 1923, Journal of Experimental Biology is the leading primary research journal in comparative physiology and biomechanics in animals. It publishes papers on the form and function of living organisms at all levels of biological organisation, from the molecular and subcellular to the integrated whole animal.

Topic coverage ranges from biochemical physiology to biomechanics, from cardiovascular and respiratory physiology to conservation physiology, from endocrinology to ecological and evolutionary physiology, and from neurobiology to neuroethology and sensory physiology.

In addition to primary research articles,
Journal of Experimental Biology publishes
a range of commissioned review-based
articles. These synthesise the latest
advances in the field, put forward new
hypotheses to provoke debate and
inspire new research directions, and
inform newcomers to the field.



Readership

Journal of Experimental Biology is read by an interdisciplinary group of scientists who study molecular, cellular and organismal physiology in an evolutionarily and environmentally based context including systemic, cellular and molecular physiologists, neuroscientists, ecophysiologists, biomechanists and biochemists.

Abstracting and indexing services

Journal of Experimental Biology is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline and Scopus.

Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals (including Journal of Experimental Biology) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are also included in our Read & Publish Open Access agreements.

- 2021 Impact Factor: 3.308
- Five-year Impact Factor: 3.879
- Two-year citation median: 2.0
- Eigenfactor score: 0.02371
- Article influence score: 1.028
- Cited half-life: 12.2
- Immediacy Index: 1.12
- h-index: 195
- Scopus CiteScore: 5.7
- SJR indicator: 1.159
- SNIP: 1.237

Journal of **Experimental Biology**

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

· Craig E. Franklin (University of Queensland, Australia)

Deputy Editors-in-Chief

- · Sheila N. Patek (Duke University, USA)
- Patricia A. Wright (University of Guelph, Canada)


Monitoring Editors

- Monica A. Daley (University of California, Irvine, USA)
- Stuart Egginton (University of Leeds, UK)
- · Kathleen M. Gilmour (University of Ottawa, Canada)
- · Almut Kelber (Lund University, Sweden)
- · Ken Lukowiak (University of Calgary, Canada)
- Matthew J. McHenry (University of California, Irvine, USA)
- Sanjay P. Sane (National Center for Biological Sciences, India)
- Patricia M. Schulte (The University of British Columbia, Canada)
- John S. Terblanche (Stellenbosch University, South Africa)


What are the benefits of Read & Publish agreements?

- Unlimited "read" access to our three subscription journals Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- Transparent cost-neutral pricing
- · Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S
- I'm happy that my first contribution to the field could be published Open Access thanks to the Read & Publish agreement my university has with The Company of Biologists. It really takes away the barriers on both sides: now anyone that wishes to read our work can do so freely, and we were able to publish our article OA despite not having publishing fees accounted for in our budget. Great initiative!

Natalie van Dis, University of Groningen, The Netherlands










Disease Models & Mechanisms



Launched in 2008, Disease Models & Mechanisms is an Open Access biomedical research journal that advances understanding of the mechanism, diagnosis and therapy of human disease.



Interdisciplinary in scope, Disease Models & Mechanisms covers a diverse range of diseases, including cancer, infectious diseases, developmental disorders, musculoskeletal disorders, and neurodegenerative and neurological diseases. Published research utilizes in vitro or ex vivo models, such as stem-cell-based models, organoids, patient material, model organisms, microorganisms, viruses and computational approaches.

In addition to research articles, Disease Models & Mechanisms features expert reviews, perspectives and interviews with leading scientists to address current and emerging themes in biomedical science.

Readership

Disease Models & Mechanisms aspires to connect and support all those working at every level of disease research, from basic researchers to clinicians at the forefront of patient care. Content is freely available to the journal's communities of basic and clinical researchers, those working for pharmaceutical companies, health professionals, patients and their advocates and families.

Abstracting and indexing services

Disease Models & Mechanisms is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline, Scopus and the Directory of Open Access Journals (DOAJ).

Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are also included in our Read & Publish Open Access agreements.

- 2021 Impact Factor: 5.732
- Five-year Impact Factor: 6.581
- Two-year citation median: 4.0
- Eigenfactor score: 0.01083
- Article Influence Score: 1.684
- Immediacy Index: 1.262
- h-index: 93
- Scopus CiteScore: 9.0
- SJR indicator: 1.874
- SNIP: 1.211

Disease Models & Mechanisms

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

• E. Elizabeth Patton (MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK)

Deputy Editor-in-Chief

• Elaine R. Mardis (Nationwide Children's Hospital, Ohio, USA)

Editors

- James Amatruda (Children's Hospital Los Angeles, CA, USA)
- Steven J. Clapcote (University of Leeds, UK)
- Tatsushi Igaki (Kyoto University, Japan)
- Monica J. Justice (The Hospital for Sick Children [SickKids], Toronto, Canada)
- Karen Liu (King's College London, UK)
- Owen Sansom (Beatson Institute for Cancer Research, Glasgow, UK)
- David M. Tobin (Duke University School of Medicine, Durham, NC, USA)


Associate Editors

- Sally Dunwoodie (Victor Chang Cardiac Research Institute, Australia)
- Monkol Lek (Yale School of Medicine, USA)
- Sumana Sanyal (University of Oxford, UK)
- Ian Smyth (Monash University, Australia)
- Eckhard Wolf (Gene Center, LMU Munich, Germany)


What are the benefits of Read & Publish agreements?

- Unlimited "read" access to our three subscription journals Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- · Transparent cost-neutral pricing
- · Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S
- The Read & Publish agreement initiative is a great advance enabling open access to research. The agreement between The Company of Biologists and my university made it simple to publish Open Access quickly and fee-free; a great incentive to publish in their suite of journals.

Dr Katharine Irvine, The University of Queensland, Australia









Biology Open



Biology Open was launched in 2012 as the first fully Open Access journal published by The Company of Biologists. It publishes rigorously conducted research that spans the breadth of the biological and biomedical sciences.



From adenovirus to zebrafish, via cancer biology and stem cells, the Biology Open team is committed to Open Access publishing as a mechanism to widen access, promote equality and ensure sustainability in publishing in the biological sciences.

Biology Open aims to support early-career researchers in particular. It publishes **First Person interviews** with the first authors of research papers, and creates career development opportunities through its early-career researcher focused **Meeting Reviews** and **Future Leader Reviews** initiative.

Readership

Biology Open is read by scientists at all career levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, and stem cell and developmental biologists, as well as scientists who study molecular, cellular and organismal physiology. Content is freely available to the journal's communities of researchers and the general public.

Abstracting and indexing services

Biology Open is abstracted and/or indexed by (amongst others): Biological Abstracts, BIOSIS, CAB abstracts, Chemical Abstracts, Clarivate Analytics Web of Science, Medline, PMC, PubMed, Scopus and the Directory of Open Access Journals (DOAJ).

Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our subscription journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals - Disease Models & Mechanisms and Biology Open), are also included in our Read & Publish Open Access agreements.

- 2021 Impact Factor: 2.643
- Five-year Impact Factor: 2.687
- Two-year citation median: 2.0
- Eigenfactor score: 0.00627
- Article Influence Score: 0.661
- Immediacy index: 0.769
- h-index: 47
- Scopus CiteScore: 4.6
- SJR indicator: 0.765
- SNIP: 0.73

Biology Open

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

• Steven Kelly (University of Oxford, UK)

Deputy Editors

- Catherine L. Jackson (Institut Jacques Monod, Paris, France)
- · Yishi Jin (University of California, San Diego, USA)
- Tristan Rodríguez (Imperial College London, UK)

Editors

- · Kendra J. Greenlee (North Dakota State University, USA)
- Lewis Halsey (University of Roehampton, London, UK)
- Sjannie Lefevre (University of Oslo, Norway)
- Christopher A. Maher (Washington University School of Medicine, USA)
- Jennifer Nichols (The University of Edinburgh, UK)
- Luca Scorrano (University of Padua, Italy)

What are the benefits of Read & Publish agreements?

- Unlimited "read" access to our three subscription journals Development, Journal of Cell Science and Journal of Experimental Biology
- Uncapped fee-free Open Access publishing of research articles in our subscription journals plus our two fully Open Access journals – Disease Models & Mechanisms and Biology Open
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S
- Biology Open is a high-quality journal which I can strongly recommend, both for reading and for publishing, and we were delighted to publish our article in it without charge under the Read & Publish agreement between The Company of Biologists and University of Southern Denmark. This is helping us to disseminate our research to as many scientists as possible.

Dr Magnus Wahlbergr, University of Southern Denmark, Denmark

